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Abstract  (152 words)  12	 ﾠ
The  diagnosis  of  tuberculosis  (TB)  currently  relies  upon  insensitive  and  non-specific  13	 ﾠ
techniques such as X-ray exams and acid-fast microscopy; newer diagnostics would ideally co- 14	 ﾠ
opt  specific  bacterial  processes  to  provide  real-time  readouts  of  disease  burden,  bacterial  15	 ﾠ
viability and response to chemotherapy.  The trehalose mycolyltransesterase enzymes (antigens  16	 ﾠ
85A, B, and C (Ag85)) serve as essential mediators of cell envelope function and biogenesis in  17	 ﾠ
Mycobacterium tuberculosis (Mtb). We show here that the Ag85 enzymes have exceptionally  18	 ﾠ
broad  substrate  specificity,  allowing  exogenously  added  synthetic  carbohydrate  probes  19	 ﾠ
structurally similar to trehalose (Tre) to be incorporated into Mtb growing in vitro and within  20	 ﾠ
macrophages.  Even  very  large  substituents,  such  as  in  the  fluorescein-containing  Tre  probe  21	 ﾠ
(FITC-Tre) were incorporated by growing bacilli thereby producing fluorescent bacteria. The  22	 ﾠ
addition of FITC-Tre to Mtb-infected macrophages allowed selective, sensitive detection of Mtb  23	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ2	 ﾠ
	 ﾠ 2	 ﾠ
within infected mammalian macrophages. These studies suggest that analogs of Tre may prove  1	 ﾠ
useful as probes for other imaging modalities.  2	 ﾠ
  3	 ﾠ
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Introduction  1	 ﾠ
TB is an infection that has plagued mankind for millennia. It remains a leading cause of  2	 ﾠ
death worldwide and was implicated in an estimated 1.6 million fatalities in 2005
1. A substantial  3	 ﾠ
obstacle to the development of new diagnostics, drugs, and vaccines is the lack of TB-specific  4	 ﾠ
probes that can be used to rapidly assess infection and monitor response to treatment
2. The cell  5	 ﾠ
envelope  of  Mtb  poses  a  significant  permeability  barrier  that  contributes  to  the  intrinsic  6	 ﾠ
difficulties in eradicating this disease  since it effectively precludes entry of most substances  7	 ﾠ
(including potential drugs and probes) to the bacterial cytoplasm
3-6.   8	 ﾠ
The non-mammalian, disaccharide sugar trehalose, Tre (1 , Scheme 1) is synthesized by Mtb  9	 ﾠ
through  three  independent  pathways  and  genetic  knockouts  of  any  of  these  three  pathways  10	 ﾠ
results  in  either  non-viable  Mtb  or  organisms  displaying  growth  defects
7-11.  Because  of  this  11	 ﾠ
essentiality,  targeting  the  trehalose  pathway  may  be  an  important  approach  to  TB  drug  12	 ﾠ
development. Trehalose is found in the outer portion of the mycobacterial cell envelope along  13	 ﾠ
with  the  glycolipids  trehalose  dimycolate  (TDM,  Scheme  1)  and  trehalose  monomycolate  14	 ﾠ
(TMM, Scheme 1).
12,13  TMM and TDM are important glycolipids for Mtb, capable of inducing  15	 ﾠ
granuloma  formation  in  the  absence  of  infection
14-16.	 ﾠ Mycolic  acids  are  long  (C60-C90),  16	 ﾠ
cyclopropanated lipids found in the cell wall of Mtb, which are important for bacterial outer  17	 ﾠ
membrane  structure,  virulence  and  persistence  within  the  host.
17  Tre  is  anchored  into  the  18	 ﾠ
mycobacterial  cell  wall  as  mono-  (TMM)  or  di-  (TDM)  mycolates  by  the  action  of  the  19	 ﾠ
extracellular  proteins  Ag85  A,  B,  and  C.  Although  these  proteins  were  long  known  to  20	 ﾠ
immunologists by virtue of their immunogenicity, their enzymatic activity was first described in  21	 ﾠ
1982 as the active fraction of a cell free extract from Mycobacterium smegmatis that was capable  22	 ﾠ
of synthesizing TDM
18. Ag85A, Ag85B and Ag85C are the most abundant secreted Mtb proteins  23	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ4	 ﾠ
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in vitro, accounting for as much as 41% of the total protein in culture supernatant
19. Individual  1	 ﾠ
knockouts of the genes that code for single members of the Ag85 family have significant effects  2	 ﾠ
on total cellular mycolic acid content
20-22; triple knockouts of the ag85ABC genes have not been  3	 ﾠ
reported  in  Mtb,  presumably  because  they  are  not  viable.  Ag85  isoforms  all  catalyse  the  4	 ﾠ
reversible transesterification reaction between two units of TMM, generating TDM and free Tre  5	 ﾠ
(Scheme  1);  the  reverse  reaction  also  allows  for  direct  esterification  of  Tre.  Ag85  can  also  6	 ﾠ
covalently  introduce  mycolates  into  arabinogalactan  to  form  the  base  polymer  of  the  cell  7	 ﾠ
wall
22,23.   8	 ﾠ
<Scheme 1>  9	 ﾠ
Ag85A, Ag85B, and Ag85C share high sequence and structural homology 
24-26, characterized  10	 ﾠ
by an α,β-hydrolase fold and a hydrophobic fibronectin-binding domain. Their active sites are  11	 ﾠ
highly conserved, featuring a His, Asp/Glu, Ser catalytic triad, a hydrophobic tunnel for the  12	 ﾠ
lipids  and  two  trehalose  binding  sites  (Figure  1a).  These  characteristics  suggest  a  13	 ﾠ
transesterification mechanism analogous to that of serine hydrolases, in which the formation of a  14	 ﾠ
covalent Ser-mycolic acid enzyme intermediate is followed by attack from the 6-hydroxyl of  15	 ﾠ
Tre
24.   16	 ﾠ
<Figure 1>  17	 ﾠ
Structural analysis (Figure 1b) of Tre bound to Ag85B suggested positions (C-4’ and C-2) on  18	 ﾠ
Tre that were directed outward towards solvent and that might tolerate substitutions and yet  19	 ﾠ
retain activity as substrates for Ag85. Although trehalose itself has been demonstrated to be a  20	 ﾠ
substrate of Ag85
18,27,28 and its uptake and utilization by M. smegmatis has been observed,
10,29  21	 ﾠ
Tre uptake into whole-cells of Mtb has not been investigated in detail
30,31 and corresponding  22	 ﾠBackus	 ﾠet	 ﾠal	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 ﾠ page	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activities of Tre analogs have not been explored. We show here that not only are Ag85A, Ag85B  1	 ﾠ
and  Ag85C  sufficiently  promiscuous  to  process  a  variety  of  trehalose  analogs  with  good  2	 ﾠ
efficiency but that trehalose and Tre-probe analogs are also efficiently anchored to Mtb. We have  3	 ﾠ
exploited this substrate tolerance by designing fluorescent trehalose probes that are processed by  4	 ﾠ
Ag85  and  that  allow  fluorescent  labeling  of  Mtb  in  a  selective  manner.  Our  findings  arm  5	 ﾠ
tuberculosis biologists with the first fluorescent small-molecule probe to label Mtb not only in  6	 ﾠ
culture but also in infected macrophages.  7	 ﾠ
  8	 ﾠ
  9	 ﾠ
RESULTS  10	 ﾠ
Exogenous Trehalose is incorporated into TMM and TDM by Whole cells of Mtb   11	 ﾠ
We first sought to conclusively demonstrate that trehalose is taken up by live cells of Mtb  12	 ﾠ
in  vitro.  Unlike its  fast-growing  relative M.  smegmatis  which  has  28  sugar  transporters, the  13	 ﾠ
genome of Mtb encodes only five sugar permeases, suggesting that extracellular trehalose might  14	 ﾠ
not be efficiently taken up by mycobacteria
29,32. Extracellular incorporation of Tre into TMM or  15	 ﾠ
TDM, on the other hand, would not require transport across the cell envelope. Using comparative  16	 ﾠ
radioprobes 
14C-acetate, 
14C-glycerol, 
14C-glucose  and 
14C-trehalose  we  measured  uptake  in  17	 ﾠ
pathogenic Mtb over 2 and 24h time periods (Figures 2a and S1)
33. Tre uptake was significant  18	 ﾠ
and the strongest band labeled by 
14C-Tre co-migrated with a band labeled by 
14C-acetate and co- 19	 ﾠ
migrated with cold TMM. 
14C-Tre also labeled a band that co-migrated with TDM, although not  20	 ﾠ
labeled to the same extent as TMM. To confirm that these bands were TMM and TDM we also  21	 ﾠ
labeled cells following treatment with isoniazid (INH), which inhibits mycolic acid biosynthesis  22	 ﾠ
and therefore blocks production of both TMM and TDM. As shown in Figure 2c (lanes 3 and 4)  23	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ6	 ﾠ
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INH effectively blocks biosynthesis of these two bands. Together these results demonstrated that  1	 ﾠ
Tre is taken up by the bacteria and incorporated into TDM and TMM by Mtb in vitro.   2	 ﾠ
Mtb  is  thought  to  infect  the  alveolar  macrophages  that  line  the  lung  epithelium;  3	 ﾠ
macrophage  uptake  therefore  represents  an  additional  permeability  hurdle  that  separates  any  4	 ﾠ
potential probe from Mtb.
34 We therefore labeled Mtb-infected J774 cells (a murine macrophage- 5	 ﾠ
like cell line) and separately analyzed the macrophage supernatant, crude lysate and insoluble  6	 ﾠ
fractions (Figure 2b) of both infected and uninfected cells. Not only did 
14C-Tre successfully  7	 ﾠ
penetrate and internalize into murine macrophages, it was also subsequently taken up by Mtb  8	 ﾠ
growing within these cells, thereby validating the potential of Tre probes in vivo.  9	 ﾠ
<Figure 2 >  10	 ﾠ
  11	 ﾠ
Design and Synthesis of a Tre-analog Library  12	 ﾠ
To fully explore the potential of Tre analogs as possible selective probes of Mtb, we  13	 ﾠ
designed and synthesized (see SI for details) a panel of compounds (Scheme 2) that would allow  14	 ﾠ
us to evaluate the substrate tolerance of Ag85 isoforms. This library of Tre analogs featured  15	 ﾠ
systematic  modifications  at  each  position  to  explore  the  enzyme  active  site  in  detail.  Such  16	 ﾠ
trehalose  derivatives  present  unique  synthetic  challenges:  creating  the  link  between  the  two  17	 ﾠ
glucose units requires that two difficult
35 stereocenters be established simultaneously and the  18	 ﾠ
symmetry of the Tre scaffold itself necessitates potentially complex asymmetric modifications.  19	 ﾠ
Elegant intramolecular, aglycone-tethered glycosylation strategies
36 have allowed access to some  20	 ﾠ
C-2  modifications  and  stereocontrol,  yielding  the  α,α(1,1)-anomeric  configuration  found  in  21	 ﾠ
natural Tre, but are limited in their scope of diversification. Most previous modifications of the  22	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ7	 ﾠ
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 ﾠ
Tre  scaffold,  including  previously  designed  inhibitors  of  Ag85,  have  focused  only  on  1	 ﾠ
modifications at C-6 and C-4
28,37-42.   2	 ﾠ
Our Tre-probe library was synthesized using complementary strategies for i) directly creating  3	 ﾠ
the 1,1-linkage in Tre (Scheme S1) and ii) precise Tre scaffold alteration (Scheme S1) allowing  4	 ﾠ
access to analogs 2-22 bearing alterations in both the functional groups and in the stereochemical  5	 ﾠ
configurations found at all positions C-1, 2, 3, 4 and 6 in Tre. Functional groups were chosen for  6	 ﾠ
incorporation that might provide later use in the design of imaging probes such as fluorine (2-F,  7	 ﾠ
3-F, 4-F, 6-F derivatives) for potential use in 
18F-PET and amines for late-stage attachment of  8	 ﾠ
chromophores, radiolabels and fluorophores.  9	 ﾠ
1,1-Linkage  formation  was  accomplished  in  three  ways:  a)  ketoside  formation
43-49  b)  10	 ﾠ
dehydrative  glycosylation
50  and  c)  chemoenzymatically
9,51,52.  Full  characterization  of  the  11	 ﾠ
synthesized probes included unambiguous assignment of stereochemistry using NMR (NOE and  12	 ﾠ
H-1 coupling constants). Methyl ketosides and exo-glycals proved to be excellent reagents for  13	 ﾠ
α,α-selective synthesis of asymmetric trehalose from a wide range of modified coupling partners,  14	 ﾠ
including derivatives of glucose, 2-deoxy-2-fluoro-glucose, 3-deoxy-3-fluoro-glucose, and 2-N- 15	 ﾠ
carbobenzyloxy-amino-glucose, yielding Tre-analogs 2-7 in good overall yields (30-90%) after  16	 ﾠ
deprotection (see SI). Symmetric dideoxy 10, diiodo 12 and difluoro 13,14 trehalose analogs  17	 ﾠ
were accessed through dehydrative dimerization reactions.
50 2-deoxy-2-fluoro-trehalose 22 was  18	 ﾠ
synthesized using a multi-step enzymatic route. Finally, Tre-scaffold modifications employed  19	 ﾠ
regioselective protecting group manipulation
41,42,53-55 to allow selective asymmetric access and  20	 ﾠ
replacement of hydroxyl groups at positions 4 and 6 (see SI for full details).  21	 ﾠ
<Scheme 2>  22	 ﾠBackus	 ﾠet	 ﾠal	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 ﾠ page	 ﾠ8	 ﾠ
	 ﾠ 8	 ﾠ
Together  these  synthetic  routes  allowed  ready  access  to  Tre  analogs  2-22  containing  1	 ﾠ
modifications such as 1-methyl 2-9, 2-fluoro 3,5,13,14,22, 2-iodo 12, 2-deoxy 10,11 3-fluoro 6,  2	 ﾠ
4-fluoro 21, 6-fluoro 20, 6-bromo 19, 6-phosphate 15-17, 6-azido 18 and even stereoisomers  3	 ﾠ
4,5,11 and allowed access to intermediates such as 2-amino-Tre 7 onto which imaging labels  4	 ﾠ
fluorescein (in 9), fluorobenzyl (in 8) and even quantum dots (in Tre-QD, see SI) could be  5	 ﾠ
coupled.  6	 ﾠ
  7	 ﾠ
A Novel Assay of Trehalose Processing  8	 ﾠ
The substrate specificity and a full kinetic analysis of the Ag85 enzymes has not previously  9	 ﾠ
been fully attempted, presumably because of the difficult nature of the radiochemical assay using  10	 ﾠ
natural substrates. Heterogeneity in the mycolic fatty acid chain length (C30-C90), as well as low  11	 ﾠ
solubility of both substrates and products in aqueous media has complicated prior assays. The  12	 ﾠ
widely employed 
14C-Tre radioassay
56 monitors 
14C-Tre radiolabel incorporation into TDM and  13	 ﾠ
TMM yielding, at best, approximate kcat(app) values; such assays have suggested that  Ag85B has  14	 ﾠ
a lower (~20%) activity than Ag85A and Ag85C
56.   15	 ﾠ
<Table 1>  16	 ﾠ
<Scheme 3>  17	 ﾠ
Mass spectrometric analysis
57,58 provided a rapid means to screen Tre analogs 1-24 as  18	 ﾠ
substrates  of  all  Ag85  isoforms  (Table  1).  Ag85A,  Ag85B  and  Ag85C  were  prepared  and  19	 ﾠ
purified as previously described
56,59,60 (see SI Figures S2-S8). We designed an assay
58 based on  20	 ﾠ
the use of precise, homogeneous mono and dihexanoyl Tre substrates, which proved to be water  21	 ﾠ
soluble and readily turned over by Ag85 allowing the development of a broad Ag85 substrate  22	 ﾠ
screen (Scheme 3). A calibrated green-amber-red (GAR)
57,61 screen for catalysis of transfer of  23	 ﾠ
None* up to 200ug/mL 
** signification growth inhibition at 200 Backus	 ﾠet	 ﾠal	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 ﾠ page	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the  acyl  chain  from  natural  Tre  to  unnatural  Tre-analog  (Tre*),  using  these  pure  synthetic  1	 ﾠ
substrates allowed determination of relative reactivity ratios Tre*:Tre (Table 1). Importantly, this  2	 ﾠ
screen revealed a strong selectivity for Tre-like disaccharides over monosaccharides such as D- 3	 ﾠ
glucose (23) but a striking plasticity for all tested Tre analogs. Modifications on every position of  4	 ﾠ
the sugar scaffold were tolerated including even C-1 methyl groups at the crowded anomeric  5	 ﾠ
linkages in 2-9; positive charges, such as in the 2-amino-trehalose 7 and even stereochemically  6	 ﾠ
‘incorrect’  2,2’-di-fluoro-αβ-manno-trehalose  14.  Even  a  previously  reported  inhibitor
56,  6- 7	 ﾠ
azido-Tre 18 and putative tetrahedral transition state analogs, such as trehalose-6-phosphate 16,  8	 ﾠ
were also processed.   9	 ﾠ
Prior reports of 18 as an inhibitor (albeit a weak one with a reported MIC against a related  10	 ﾠ
mycobacterial species of 200 µg/mL)
56 prompted us to examine the possibility that these analogs  11	 ﾠ
also induced growth inhibition; minimum inhibitory concentration (MIC) analysis was therefore  12	 ﾠ
carried out on key representative compounds (Table 1). Amongst these only 2,2’-dideoxy-lyxo- 13	 ﾠ
Tre 11, which was not a substrate for any of the three Ag85 isoforms, showed an inhibitory  14	 ﾠ
effect (MIC 100 µg/mL). C-6 modified compounds that were processed well by Ag85 inhibited  15	 ﾠ
growth only at high concentrations (MIC 100-200 µg/mL). Notably, no growth inhibition with  16	 ﾠ
FITC-Tre was noted either in vitro or in infected macrophages (see SI Figure S9).  17	 ﾠ
  18	 ﾠ
FITC-Tre Specifically Labels Mtb In Vitro   19	 ﾠ
  Next we explored the uptake of fluorescent probes in growing cells of Mtb (Figure 3). The  20	 ﾠ
pathogenic Mtb strain H37Rv was grown for 24 hours in the presence of FITC-Tre and then  21	 ﾠ
washed to remove unbound dye. A significant increase in fluorescence over time was observed  22	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ10	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in bacteria exposed to FITC-Tre, relative to the autofluorescence of the control bacteria and  1	 ﾠ
relative to heat-killed Mtb that had been treated with FITC-Tre (Figure 3a, b). Heat-killed Mtb  2	 ﾠ
form large aggregates that are particularly difficult to wash adequately, perhaps contributing to  3	 ﾠ
the relatively high background observed in these organisms. To demonstrate that incorporation  4	 ﾠ
was specific we also monitored incorporation of FITC-Glucose into live cells of Mtb and found  5	 ﾠ
significantly less incorporation of label into cells (Figure 3b), consistent with the poor efficiency  6	 ﾠ
of glucose as a substrate for the Ag85 enzymes (and the unlikely uptake of this probe into the  7	 ﾠ
cell by glucose-specific transporters). To demonstrate that this incorporation was dependent upon  8	 ﾠ
Ag85  we  obtained  a  mutant  in  Ag85C  that  has  been  previously  reported  to  have  40%  less  9	 ﾠ
mycolic  acid  incorporation  into  the  mycobacterial  cell  wall
22.  This  mutant  incorporated  10	 ﾠ
approximately  30%  less  FITC-Tre  than  did  wild  type  (Figure  3a),  supporting  our  proposed  11	 ﾠ
mechanism of anchoring of FITC Tre through Ag85 mediated incorporation of mycolic acids. To  12	 ﾠ
unambiguously establish that FITC-Tre was localizing to cells by virtue of being esterified with  13	 ﾠ
mycolic acids we simultaneously labeled cells with both FITC-Tre and 
14C-acetate and isolated  14	 ﾠ
individual fluorescent spots by preparative TLC (Figure 3c). We did not make any attempt to  15	 ﾠ
characterize the other less polar spots of low abundance that also apparently incorporated FITC- 16	 ﾠ
Tre although these might reasonably be supposed to be other Tre-containing glycolipids found  17	 ﾠ
within the mycobacterial cell wall.
16 Saponification of these spots followed by methylation and  18	 ﾠ
TLC revealed that the strongly fluorescent spots carrying FITC-Tre were associated with lipids  19	 ﾠ
co-migrating with the characteristic triplet pattern of the three classes of mycolic acids (alpha,  20	 ﾠ
methoxy and keto) (Figure 3e). Finally to establish specificity of labeling we also exposed three  21	 ﾠ
other  organisms  commonly  found  in  the  human  lung  to  FITC-Tre;  Staphylococcus  aureus,  22	 ﾠBackus	 ﾠet	 ﾠal	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Haemophilus influenzae and Pseudomonas aeruginosa. None of these organisms were found to  1	 ﾠ
exhibit appreciable labeling with FITC-Tre (Figure 3b).  2	 ﾠ
<Figure 3>  3	 ﾠ
The value of FITC-Tre as a probe was demonstrated in its revelation of clear patterns of  4	 ﾠ
differential  accumulation  within  live  Mtb  (Figure  4).  For  example,  confocal  fluorescence  5	 ﾠ
microscopy of H37Rv-Mtb expressing a red fluorescent protein (RFP, here mCherry carried by a  6	 ﾠ
PMV261 plasmid) revealed higher levels of green fluorescence from FITC-Tre incorporation at  7	 ﾠ
outer membranes and, in particular, at the bacterial poles, and less in mid sections (where the  8	 ﾠ
RFP localizes, Figure 4b-d). Thi s  s pec ific  loca l ization w a s  confirme d  b y  m icros copic  s e ctions   9	 ﾠ
along  the  Z-axis  (Z-stacks,  Figure  4e)  and by  statistical  analysis  of  mean  fluorescence  (p  <  10	 ﾠ
0.0001, Figure 4f). These observations are not only consistent with the mode of action proposed  11	 ﾠ
for these Tre analogs but also suggest higher Ag85 activities at poles that appear consistent with  12	 ﾠ
a polar growth model.   13	 ﾠ
<Figure 4>  14	 ﾠ
  15	 ﾠ
FITC-Tre Specifically Labels Mtb In Vitro and Inside Mammalian Macrophages  16	 ﾠ
  We next tested the ability of these probes to selectively label Mtb in mammalian cells during  17	 ﾠ
infection. Treatment of Mtb-infected macrophages with FITC-Tre (Figure 5) demonstrated that  18	 ﾠ
the probe was internalized into macrophages with subsequent labeling of the bacteria (Figure 5a- 19	 ﾠ
c). The specificity of the label for Mtb was demonstrated by colocalization of staining with an  20	 ﾠ
Mtb-specific  antibody (ab905,  see  SI),  use  of  an  alternative  labeling  strategy,  and  failure  to  21	 ﾠ
observe labeling with FITC-Glucose (see SI Figures S10-S12). Labeling of the intra-macrophage  22	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	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bacteria was also effectively abolished by competing administration of high concentrations (10- 1	 ﾠ
100mM) of trehalose (SI Figures S13,14).  2	 ﾠ
<Figure 5>  3	 ﾠ
  In contrast to the fairly uniform labeling of bacilli observed in vitro, bacterial labeling in vivo  4	 ﾠ
was not uniform, either between cells or within a cell. We observed the same polar localization  5	 ﾠ
of label in in vivo grown cells seen in the in vitro cells, however some bacterial cells appeared to  6	 ﾠ
incorporate no label at all. By incorporating a constitutively expressed red fluorescent protein  7	 ﾠ
(RFP) in the infecting bacilli (either integratively transformed M. bovis BCG expressing the ds- 8	 ﾠ
red-1 gene,
62 or the H37Rv-Mtb mCherry variant (see above) for comparison) we observed that  9	 ﾠ
even mycobacterial cells within a single macrophage displayed very different labeling intensities  10	 ﾠ
(Figure 5d-f, g, k). We speculated that this differential FITC-Tre labeling might be relevant to  11	 ﾠ
the growth status of a particular bacterium within the cell reflective of the maturation status of  12	 ﾠ
the endosomal compartment within which they were located. TDM has been shown to inhibit  13	 ﾠ
fusion  between  vesicles
63	 ﾠ and  is  potentially  responsible  for  the  inhibition  of  phagosomal  14	 ﾠ
acidification  by  Mtb
64,65.   	 ﾠ To  test  this  hypothesis,  murine  bone  marrow  macrophages  were  15	 ﾠ
infected with RFP-expressing H37Rv and treated with FITC-Tre, with or without activation by  16	 ﾠ
interferon-γ (IFN-γ). Colocalization studies were undertaken between the H37Rv and markers  17	 ﾠ
discriminating between endosomes, phagosomes and lysosomes, including the early endosome  18	 ﾠ
associated antigen (EEA-1), Rab5
66, Rab14
67, Pro-cathepsin D
68,69, and the lysosomal associated  19	 ﾠ
membrane  protein  (LAMP-1
70).  Colocalization  was  then  assessed  by  confocal  microscopy  20	 ﾠ
between these markers and the entire bacterial population as well as the highly FITC-Tre labeled  21	 ﾠ
subpopulation.  As  expected,  low  colocalization  was  observed  both  under  activated  and  22	 ﾠ
unactivated  conditions  for  EEA-1  (see  SI  Figure  S15).  Consistent  with  previous  reports  of  23	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ13	 ﾠ
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 ﾠ
accumulation of Rab5 in the mycobacterial phagosome, we observed consistent co-localization  1	 ﾠ
of this marker with both total, and high FITC-Tre-labeled bacilli in unactivated macrophages.  2	 ﾠ
  Upon IFN-γ activation, however, Rab5 colocalization was found to be less for highly FITC- 3	 ﾠ
Tre-labeled Mtb than the bulk bacterial population (Figure 5k-n). Colocalization between Rab14  4	 ﾠ
and FITC-Tre-labeled Mtb compared to the total population of bacteria was comparable for both  5	 ﾠ
unactivated  and  IFN-γ  treated  macrophages  (SI  Figure  S16).  In  contrast,  Pro-Cathepsin  D,  6	 ﾠ
cleavage  of  which  is  a  marker  of  phagosomal  maturation  and  phago-lysosome  fusion  was  7	 ﾠ
increased  in  colocalization  with  FITC-Tre-positive  Mtb  relative  to  the  whole  population  (SI  8	 ﾠ
Figure S17). LAMP1 was also found to colocalize to a lesser degree with highly FITC-Tre  9	 ﾠ
positive bacteria (Figure 5g-j) than the population average, particularly upon IFN-γ activation.  10	 ﾠ
Together these data are consistent with the hypothesis that Mtb that poorly incorporate FITC-Tre   11	 ﾠ
tend  to  be  localized  to  Rab5-containing  phagosomes  that  have  more  fully  matured  towards  12	 ﾠ
degradative  lysosomes.  The  corollary  is  that  those  with  high  Ag85-activity  that  incorporate  13	 ﾠ
FITC-Tre well, and will therefore readily generate TDM, are associated  with less-developed  14	 ﾠ
phagosomes, perhaps through TDM-associated inhibitory mechanisms.
64,65  15	 ﾠ
  16	 ﾠ
Discussion   17	 ﾠ
Despite decades of investigation for both their immunologic and enzymatic activities, the  18	 ﾠ
Antigen  85  enzymes  remain  poorly  understood.  Little  is  known  about  the  range  of  their  19	 ﾠ
substrates and the reason for their apparent functional redundancy in Mtb. The uptake of 
14C- 20	 ﾠ
trehalose into Mtb in vitro as well as into infected macrophages suggested that Tre analogues  21	 ﾠ
may be useful in designing novel probes of TB pathogenesis. Using a novel Ag85 substrate assay  22	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ14	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we have found that Ag85A,B and C will tolerate surprisingly extensive modifications on the  1	 ﾠ
trehalose scaffold, processing well many disaccharides (but not monosaccharides).   2	 ﾠ
The  discovery  of  the  breadth  of  substrates  processed  by  Ag85  isoforms  could  have  3	 ﾠ
important  implications  for  the  biological  roles  of  these  enzymes.  The  enzyme-specific  4	 ﾠ
differences in substrate tolerance observed imply an unappreciated subtlety in the active site  5	 ﾠ
architecture  of  these  enzymes.  Numerous  glycolipids  within  Mtb  contain  a  trehalose  core,  6	 ﾠ
including, TDM, TMM, pentaacyl trehalose (PAT), triacyl trehalose (TAT) and sulfolipid-1 (Sl- 7	 ﾠ
1); little is known about the final acylation steps of PAT, TAT, and SL-1 and the enzymes of the  8	 ﾠ
Ag85 complex have been postulated to be involved in the lipidation of these compounds
71-73. The  9	 ﾠ
substrate  plasticity,  particularly  at  the  C-2  position,  may  also  have  implications  in  the  final  10	 ﾠ
acylation steps of sulfolipid-1, which are unknown, but have been postulated to potentially occur  11	 ﾠ
via antigen 85
71,74. Glucose and arabinose, both of which have been proposed as native enzyme  12	 ﾠ
substrates, are processed, albeit poorly relative to trehalose dissacharides
22,23,75. The ability to  13	 ﾠ
fluorescently  label  lipids  attached  to  trehalose  by  the  Ag85  proteins  should  be  useful  in  14	 ﾠ
identifying other pathways that may employ their transesterification activity and help clarify this  15	 ﾠ
poorly understood area of biochemistry.  16	 ﾠ
  Most excitingly, these assays have informed the design of a fluorescent probe that selectively  17	 ﾠ
labels Mtb in infected macrophages. Prior imaging work with Mtb in infected macrophages has  18	 ﾠ
utilized several strategies
76-78 but none allow for non-toxic imaging of bacteria in vivo. Bacteria  19	 ﾠ
can  be  labeled  with  Texas-Red  through  oxidation  with  sodium  periodate  prior  to  infection.  20	 ﾠ
However, these harsh labeling conditions are nonselective and would be expected to oxidize  21	 ﾠ
carbohydrates that may be structurally important as well as peripherally associated glycolipids  22	 ﾠ
that may be important for specific virulence attributes.
76,77  Fluorescently-labeled vancomycin
79  23	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has been elegantly used to track the cell division patterns of M. smegmatis and M. bovis BCG
78  1	 ﾠ
but its toxicity towards Mtb,
80 may affect experimental results. Antibodies can be utilized to label  2	 ﾠ
Mtb upon fixation and for enzyme linked immunosorbant assays (ELISA)
81, but are not useful  3	 ﾠ
for live imaging.  FITC-Tre shows no significant inhibition of Mtb growth, which suggests that it  4	 ﾠ
does not perturb natural bacterial functions thereby allowing imaging of healthy, viable bacteria.  5	 ﾠ
FITC-Tre is also selective for Mtb and readily penetrates macrophages. Unlike other possible  6	 ﾠ
probes  its  mode  of  action  is  based  on  the  activity  of  an  enzyme  unique  to  this  genus  of  7	 ﾠ
organisms.  Given the highly conserved nature of the Ag85 proteins
82-84, in mycobacteria (and  8	 ﾠ
the complete absence of Tre in mammalian biology) it is likely this probe would also label non- 9	 ﾠ
tuberculous mycobacteria as well as other members of the tuberculosis complex.  10	 ﾠ
  Our understanding of the macrophage infection  process is incomplete
85, so the ability to  11	 ﾠ
follow viable Mtb during infection shown here, could prove extremely useful as a means to  12	 ﾠ
further  understand  the  bacterial  transit  to  the  phagosome  as  well  as  other  intracellular  13	 ﾠ
compartments. The colocalization studies between FITC-Tre-labeled Mtb and various markers of  14	 ﾠ
phagosome maturation suggest that FITC-Tre may preferentially label those bacteria that resist  15	 ﾠ
acidification and phagosome-lysosome fusion. An alternative hypothesis that we cannot rule out  16	 ﾠ
is that incorporation of FITC-Tre into the membrane of a subset of bacilli alters the course of  17	 ﾠ
development of their phagosome, as has been seen with Brucella pertusis prelabeled with FITC  18	 ﾠ
before  infection
86.  Since  in  our  use  of  FITC-Tre  it  is  added  after  the  infection  has  been  19	 ﾠ
established, and is in low concentration relative to TDM, we expect the influence of the FITC- 20	 ﾠ
Tre-DM to be slight. Other trehalose-tagged molecules, potentially labeled at different positions  21	 ﾠ
or different tags on the trehalose scaffold may also prove useful as additional Mtb probes. Future  22	 ﾠ
work  with  FITC-Tre  and  related  compounds  will  hopefully  shed  more  light  on  its  in  vivo  23	 ﾠBackus	 ﾠet	 ﾠal	 ﾠ 	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potential, as a possible diagnostic tool to label Mtb in an infected host. Perhaps more excitingly,  1	 ﾠ
the broad substrate tolerance of the Ag85 proteins suggests the possibility of probes based on  2	 ﾠ
such analogs for a diverse panel of imaging modalities.  3	 ﾠ
  4	 ﾠ
Methods  5	 ﾠ
  6	 ﾠ
Chemical synthesis   7	 ﾠ
The synthesis of all reported compounds is described in the Supplementary Methods.  8	 ﾠ
  9	 ﾠ
Mass Spectrometry   10	 ﾠ
Full  details  are  described  in  the  Supplementary  Methods.  Briefly,  a  96-well  plate  was  set  up  with  each  well  11	 ﾠ
containing TDH 60 and one of the screen compounds in 1mM TEA buffer (pH = 7.2) at 37 ˚C. To each well was  12	 ﾠ
added by automated injection (with mixing), 20 µL of either Ag85A/B/C or buffer alone to give final concentrations  13	 ﾠ
of 500 µM of each substrate and 2 µM of Ag85. The samples were incubated at 37 °C for 2h 40 min before injection  14	 ﾠ
of a 10 µL aliquot directly into the mass spectrometer. The resulting mass spectra were measured in ESI-continuum  15	 ﾠ
mode (150-1000 Da), corrected for baseline subtraction and smoothed. The peak intensities for mono-hexanoylated  16	 ﾠ
product and remaining substrate 26 were measured and the product/substrate ratio calculated for each well.   17	 ﾠ
  18	 ﾠ
14C-Trehalose uptake into infected macrophages  19	 ﾠ
 Murine J774 macrophage cells were grown to confluence in Dulbecco’s MEM containing 10% fetal bovine serum,  20	 ﾠ
1 mmol/L L-glutamine, and 1% pyruvate (DMEM) in two 75 mL tissue culture flasks. The medium was exchanged  21	 ﾠ
and one flask of cells was infected with an MOI of 10 Mtb/macrophage of H37Rv bacteria. After 3 h, cells were  22	 ﾠ
washed with DMEM. Following 24 h incubation, the medium was exchanged and 
14C-Trehalose (10 µCi) was added  23	 ﾠ
to both infected and uninfected cultures. Cells were incubated with 
14C-trehalose for a further 24 h. Media was  24	 ﾠ
removed and the supernatant clarified by centrifugation. Macrophages were gently washed with DMEM and lysed  25	 ﾠ
with PBS containing SDS 0.1% (10 mL). Cells were further washed with PBS buffer (2 × 5 mL) and lysate was  26	 ﾠBackus	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collected in falcon tubes and vortexed (1 min). The lysate was centrifuged at 3600 rpm for 20 min and supernatant  1	 ﾠ
was poured off and collected for scintillation counting. The pelleted Mtb, as well as controls were treated with four  2	 ﾠ
wash cycles of pelleting and  resuspension (4 × 800 µL PBS with 0.1% Tween 80). The pellet was resuspended in a  3	 ﾠ
minimal amount of PBS (200 µL) and added to scintillation fluid.   4	 ﾠ
  5	 ﾠ
14C- and FITC-Tre lipid extractions  6	 ﾠ
Lipid extractions from bacteria treated with 
14C-trehalose and 
14C-acetate and were conducted based on adaptations  7	 ﾠ
of radiolabelling from previous reports
87 and analyzed by radiographic TLC. 
14C-trehalose (10 µCi/tube) or 
14C- 8	 ﾠ
acetate (30 µCi/tube) or dual 
14C-acetate (30 µCi/tube) and FITC-trehalose (to final concentration of 100 µM) were  9	 ﾠ
added to 15 mL H37Rv OD650 of 0.8. Cells were harvested and extracted into 2 mL (2:1 chloroform:methanol). The  10	 ﾠ
organic layer was removed, concentrated and the residue was resuspended in 200 µL (80:20 chloroform:methanol)  11	 ﾠ
and  50  µL  was  spotted  onto  silica  TLC  plates,  which  were  developed  for  1  hour  (75:25:4  12	 ﾠ
chloroform:methanol:water). Plates were scanned for fluorescence and exposed to a phosphor storage plate, which  13	 ﾠ
was  scanned  for  radioactivity.  See  Supplementary  Methods  for  isoniazid  inhibition  of  mycolate  synthesis  and  14	 ﾠ
mycolate saponification.   15	 ﾠ
  16	 ﾠ
FITC-Tre and FITC-Glc uptake into Mtb   17	 ﾠ
To CDC1551 Mtb or the Ag85C mutant of CDC1551(TBVTRM) in Middlebrook 7H9 media (10 mL) at an OD650 of   18	 ﾠ
0.44 was added FITC-Tre 9 in ethanol to a final concentration of 100µM. Heat-killed (80 ˚C, 60 min) bacteria (2 ×  19	 ﾠ
0.5 mL) at an OD650 of  0.6 were used as control. Mtb were incubated at  37 °C with shaking. After 8 hours, the  20	 ﾠ
culture (4 × 400 µL) was harvested by centrifugation (1 min, 12000 rpm)  and washed (3 x 1 mL 7H9 media) and  21	 ﾠ
resuspended (200 µL 7H9). Fluorescence measurements were conducted in 96-well format in appropriate plates  22	 ﾠ
(Nunc, Cat No 137103 (Roskilde, Denmark)). The background of the culture was obtained from cells treated in an  23	 ﾠ
identical fashion in the absence of FITC-Tre. Experiments were conducted in quadruplicate. Uptake was normalized  24	 ﾠ
for increase in OD650. FITC-Glc 28 uptake (100µM) into CDC1551 and FITC-Tre 9 uptake into H. influenzae, P.  25	 ﾠ
aeruginosa and S. aureus was conducted in an analogous manner.  26	 ﾠ
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Visualization of FITC-Tre uptake into infected macrophages   1	 ﾠ
In vitro: H37Rv-Mtb expressing RFP were grown in 7H9 medium to an OD = 0.25 at which point FITC-Tre 9 in  2	 ﾠ
ethanol was added to a final concentration of 200 µM and the culture was incubated with shaking for 24 h. The  3	 ﾠ
culture was then harvested and washed (3 × 1 mL PBS) by centrifugation and fixed in 5% formalin (1:1 in PBS).  4	 ﾠ
The culture was pelleted  and resuspended in PBS (200 µL) and mounted in suitable medium (Prolong GOLD,  5	 ﾠ
Invitrogen).  6	 ﾠ
In  vivo: B o n e M a r r o w  ma c r o p h a ge s  (BM M s )  we r e  o bt ain e d  a s  re p o r t e d  p re v i o u s l y
88.    J774  Macrophages  and  7	 ﾠ
BMMs were grown to confluence in supplemented DMEM on sterile coverslips. Cells treated with IFN-γ were  8	 ﾠ
exposed to 5 ng/mL mouse IFN- γ (Thermo RM200120) 18 hours prior to infection. BMMs and J774s were infected  9	 ﾠ
with H37Rv  Mtb (2-3 bacteria/macrophage). After 4 h of infection,  macrophages were washed  to remove free  10	 ﾠ
bacteria  and  FITC-Tre  9 w a s  a d d e d  i n  e t h a n o l  t o  a  2 0 0  µ M  f i n a l  c o n c e n t r a t i o n .  IFN-γ  was  replenished  after  11	 ﾠ
washing.  Red fluorescent protein (RFP) expressing BCG and H37Rv were infected using an identical procedure.  12	 ﾠ
Cells  were  fixed  at  different  timepoints  (24  h  or  40  h)  in  5%  formalin  (1:1  in  PBS)  and  coverslips  were  13	 ﾠ
permeabalized,  blocked  and  labeled  with  primary  and  secondary  antibodies  (see  SI  for  full  details),  following  14	 ﾠ
standard immunocytochemical methods. Cells treated with just FITC-Tre 9 were mounted in the same manner, in  15	 ﾠ
the absence of antibody. For cells labeled with DAPI, a 0.1 mg/mL stock solution of DAPI was made up in DMF  16	 ﾠ
and cells were incubated with 1µg/mL DAPI solution for 5 minutes immediately prior to mounting.    17	 ﾠ
  18	 ﾠ
Microscopy   19	 ﾠ
Images of stained cells were obtained by confocal microscopy (Leica SP5 equipped with AOBS and a white light  20	 ﾠ
laser, L e i c a  M i c r o s y s t e m s ,  E x t o n ,  P A )  u s i n g  a  6 3 ×  o i l  i m m e r s i o n  o b j e c t i v e  N A  1 . 4 .  I m a g e s  w e r e  g a t h e r e d   21	 ﾠ
sequentially and stacked when DAPI was used to label cell so as to minimize cross-talk between channels. Essential  22	 ﾠ
sequential Z sections of stained cells were also recorded for generation of stacked images through cell. A 3-D  23	 ﾠ
volume was constructed from sequential Z sections of cells assembled into a 3D volume in Imaris software (version  24	 ﾠ
7.0.0,  Bitplane  AG,  Zurich,  Switzerland).  All  collected  images  for  analyses w e r e  d e c o n v o l u t e d  b y  H u y g e n s   25	 ﾠ
Essential  software  (Version  3.4,  Scientific  Volume  Imaging  BV,  Hilversum,  The  Netherlands).  Percentage  26	 ﾠ
colocalization was calculated using the colocalization function in Imaris. ROIs for the poles and mid-sections were  27	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quantitated using the ‘marching cubes’ tool in Imaris to manually generate surfaces from which statistics were  1	 ﾠ
calculated for the regions of interest.  2	 ﾠ
  3	 ﾠ
Further experimental details can be found in the Supplementary Methods.  4	 ﾠ
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 ﾠ
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Scheme 1. Ag85A, Ag85B, and Ag85C catalyzed transesterification of trehalose 1, trehalose 
dimycolate (TDM) and trehalose monomycolate (TMM). Backus	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Figure 1. The x-ray crystal structure (PDB accession code 1F0P) of Ag85B suggests significant 
modification of trehalose substrates may be tolerated without altering binding contacts. (a) 
Ag85B in surface representation binds trehalose (stick model with carbon depicted as yellow and 
oxygen as red) in its active site as shown. (b) An expanded view of this active site region of 
Ag85B reveals that the C-2 and C-4ƹ′ hydroxyl groups of trehalose are directed out of the active 
site towards unobstructed regions. C-6 points into a hydrophobic tunnel (blue) that is thought to 
accommodate the long fatty acyl chains of the mycolic acids. Measurements of the distance from 
key trehalose atoms to the nearest residues in the protein are indicated in angstroms. Figure 
generated in Pymol. Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ32	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Figure 2. Exogenously added trehalose is incorporated into TMM and TDM in vitro and in 
macrophages infected with Mtb. (a) Incorporation of 
14C-trehalose into cell-associated counts in 
an Mtb culture over 24 h. (b) 
14C-trehalose was added either to Mtb-infected (i, iii, v), or to 
uninfected (ii, iv, vi) macrophages for 24 h. The supernatant was separated (and measured giving 
rise to ‘extracellular’ counts) and the macrophages were lysed prior to the separation of bacteria 
by  centrifugation.  The  second  supernatant  resulting  from  this  separation  was  measured  for 
‘cytoplasm’ counts and the pellet measured for ‘intracellular’. Radioactive trehalose is found in 
the cytoplasm fraction of both infected and uninfected macrophages but is incorporated into 
mycobacterial cells in infected macrophages. (c) 
14C-trehalose is incorporated into TMM and 
TDM in Mtb. Arrowheads show the migration position of authentic samples of TMM and TDM. 
In the first lane the culture was labeled for 24 h with 
14C-acetate to label all fatty acids and then Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ33	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extracted as described in the Methods. In the second lane the culture was labeled with 
14C-
trehalose for 24 h and then extracted. In the third and fourth lanes the culture was treated with 10 
× and 1× MIC concentrations of isoniazid (INH) to block the synthesis of mycolic acids and 
thereby inhibit formation of TMM and TDM. 
14C-Trehalose labels spots that co-migrate with 
TMM and TDM, the synthesis of which is blocked by INH. Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	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Scheme 2. Library of trehalose compounds and analogs. Numbered compounds correspond to 
those in the GAR screen (see Table 1). Key modifications in the trehalose analogs (2-22) are 
highlighted in red and bold. Synthesis and characterization of all compounds are described in the 
Supplementary Information. 
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Scheme 3. Simplified Antigen 85 turnover assay. Tre* represents any trehalose analog (the 
chosen example here corresponds to compound 3 from the library but the assay uses essentially 
analogous reactions for all other substrates). Mass spectrometry is utilized to quantify the amount 
of acyl-transfer to the trehalose analog (forming, for example, Mono-Hex* from Tre*) by 
Antigen 85.Backus	 ﾠet	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Table 1. Green-amber-red (GAR) screen of trehalose analogs. Compound numbers in 
Scheme 2 correspond to numbers in Table 1. The row detailing FITC-Tre compound 9 is shown 
in bold. Substrate response is expressed as percentage of the natural substrate response:>75% = 
Dark Green, 25-75% Light Green, 5-25% = Amber, <5% = Red. (Response = Peak height 
(mono-Hex*)/Peak height (Tre*)). Minimum inhibitory concentration (MIC). “†>200µg/mL” 
has some growth inhibition at 200 µg/mL. MIC50 = concentration causing 50% growth 
inhibition. ND = not determined. 
 
 
 
 
Compound  Ag85A  Ag85B  Ag85C  MIC  MIC50 
1  100  100  100  >200 µg/mL  >200 µg/mL 
2  32  13  111  >200 µg/mL
  >200 µg/mL
 
3  73  1415  102  >200 µg/mL  >200 µg/mL 
4  12  7  57  >200 µg/mL  >200 µg/mL 
5  19  13  64  >200 µg/mL  >200 µg/mL 
6  7  8  76  >200 µg/mL  >200 µg/mL 
7  47  56  91  >200 µg/mL  >200 µg/mL 
8  25  14  81  >200 µg/mL  >200 µg/mL 
9  31  38  44  >200 µg/mL  >200 µg/mL 
10  50  16  129  >200 µg/mL  >200 µg/mL 
11  1  4  1  100 µg/mL  ND 
12  148  54  166  >200 µg/mL  >200 µg/mL 
13  66  24  98  >200 µg/mL  >200 µg/mL 
14  38  35  82  >200 µg/mL  >200 µg/mL 
15  6  4  28  >200 µg/mL  >200 µg/mL 
16  37  24  113  †>200µg/mL  ND 
17  18  17  94  >200µg/mL  >200µg/mL 
18  37  13  49  †>200µg/mL  135 µg/mL 
19  102  92  99  200µg/ml  134 µg/mL 
20  149  412  91  200µg/ml  75 µg/mL 
21  229  162  191  100µg/ml  50 µg/mL 
22  115  156  274  >200 µg/mL  >200 µg/mL 
23  18  19  45  >200 µg/mL  >200 µg/mL 
24  6  28  8  >200 µg/mL  >200 µg/mL Backus	 ﾠet	 ﾠal	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 Figure 3. FITC-Tre is incorporated by Mtb into FITC-TDM through the action of the Ag85 
enzymes. (a) Uptake of FITC-Tre into wildtype CDC 1551 (purple squares) or 85C mutant, 
known to have a 40% reduction in mycolic acid incorporation into the cell wall (blue diamonds). 
(b) Uptake of FITC-Tre or FITC-Glc into (i , iii, and iv), live Mtb (ii), heat killed Mtb (v), 
Staphylococcus aureus (vi), Pseudomonas aeruginosa, (vii) Haemophilus influenza, (viii) Mean 
autoflorescence of H. influenza as representative of autofluorescence of non-mycobacterial 
species. (c) FITC-Tre is incorporated into a dimycolate, as shown by dual labeling with FITCTre 
and 
14C-acetate. Lane (i) shows the radio-TLC from single labeling with 
14C-acetic acid. Lane Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	 ﾠ38	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(ii) shows the radio-TLC that results from dual labeling using both 
14C-acetic acid and FITC-Tre. 
Lane (iii) shows the fluorescence intensity across the same lane as shown in (ii). Lane (iv) shows 
untreated FITC-Tre in the same TLC system. (d) The glycolipids extracted from these dual 
labeling experiments in co-migrate with TDM contain mycolic acids. (1)-(8) correspond to the 
individual spots labeled in lane (ii) of the radio-TLC shown in (c) that were excised, hydrolyzed 
to release fatty acids, methylated and run on a second TLC. The glycolipids in spots (6) and (7) 
contain lipids that co-migrate with authentic mycolic acids. These also display the characteristic 
banding pattern of the three major forms of these lipids. Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	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Figure 4. (a) H37Rv-Mtb are labeled with FITC-Tre and show signification accumulation of 
probe at the bacterial poles and membrane. (b) shows FITC-Tre labeling of the RFP (mCherry) 
expressing strain of H37Rv and (c) is the DIC image of (b), while (d) is an overlay of (b-c) and 
(e) depicts the Z stack (1-10) through the same image (step size of 0.13 µm) and demonstrates 
the FITC-Tre localization to the poles and membrane. (f) The mean fluorescence of poles and 
midsections of H37Rv Mtb, labeled with FITC-Tre, are quantified and show statistically 
significant differential labeling. RFUs = relative fluorescence units. Scale bars 5 µm. Backus	 ﾠet	 ﾠal	 ﾠ 	 ﾠ page	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Figure 5. Heterogeneous labeling of individual bacilli within infected macrophages. 
Macrophages were infected with H37Rv-Mtb or M. bovis BCG expressing red fluorescent 
protein (RFP) where indicated. (a-c) J774 macrophages infected with H37Rv-Mtb and labeled 
with FITC-Tre. In the DIC image (b) the bacilli are indicated by yellow arrows. The merged 
image (c) shows good colocalization of FITC-Tre and Mtb. (d-f) depict J774 macrophages 
infected with BCG, expressing RFP (ds-red-1). (d) shows green labeling from FITC-Tre, (e) 
shows red labeling from RFP and (f) shows the merged images for (d) and (e). (g-i) illustrate Backus	 ﾠet	 ﾠal	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 ﾠ page	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triple labeling colocalization studies with RFP, FITC-Tre and anti-LAMP-antibody in bone 
marrow macrophages (BMMs) activated with IFN-γ. Yellow arrows indicate red bacteria that are 
not green, ie do not take up FITC-Tre and that colocalize to a high degree with LAMP-1. (g) 
shows the merged RFP and FITC images, (h) shows the labeling with anti-LAMP-1 (magenta) 
with colocalization indicated in white, (i) shows a three dimensional reconstruction with all three 
labels superimposed. (j) shows the quantitation of this colocalization of LAMP-1 with bacteria 
that were labeled with FITC-Tre (green bars) or were red (total population). P-Values: Green vs. 
Total (ns), Green vs. Green+IFN-γ (0.006), Green vs. Total+IFN-γ (0.006), Total vs. Green + 
IFN-γ (0.01), Total vs Total+ IFN-γ (0.001) and Green+IFN-γ vs. Total+ IFN-γ (0.1). (k-m) 
depict colocalization studies with anti-Rab5 similarly infected and activated as in (g-i). Yellow 
arrows indicate red bacteria that are not green and that colocalize to a high degree with Rab5. (k) 
shows the merged RFP and FITC images, (l) shows the labeling with anti-Rab5-antibody 
(magenta) with colocalization indicated in white, (m) shows a three dimensional reconstruction 
with all three labels superimposed. (n) shows quantitation of colocalization of Rab5 with bacteria 
that were labeled with FITC-Tre (green bars) or were red (total population). P-Values: Green vs. 
Total (ns), Green vs. Green+IFN-γ (0.07), Green vs. Total+IFN-γ (0.02), Total vs. Green + IFN-
γ (0.04), Total vs Total+ IFN-γ (0.008) and Green+IFN-γ vs. Total+ IFN-γ (ns). Error bars 
reflect standard error of the mean (SEM) for a minimum of three experiments. P value > 0.1 are 
notated not significant (ns). Scale bars 5 µm. 
 